正赴港IPO的迈威生物(688062.SH)，公司董事长被证监会立案。 5月9日，迈威生物公告显示，公司董事长兼总经理刘大涛因涉嫌短线交易，中国证监会决定对其立案。 长江商报记者发现，当前，尽管有三大产品成功上市，但迈威生物的业绩依旧十分难看。 6年来，迈威生物营业收入累计达4.1亿元，净利润亏损约54亿元。其中，2023年和2024年，公司连续两 年亏损超过10亿元。 2025年一季报显示，公司实现营业收入4478.85万元，同比下降33.70%；净利润亏损2.92亿元，同比下 降41.85%。截至2025年一季度末，迈威生物资产负债率达69.86%，为上市后最高水平。 刘大涛持股市值超3亿 5月9日，迈威生物发布公告，公司收到公司董事长兼总经理刘大涛通知，其于近日收到中国证券监督管 理委员会出具的《立案告知书》，因涉嫌短线交易，中国证监会根据相关法律法规，决定对其立案。 迈威生物表示，本次事项系对刘大涛的调查，不会对公司日常经营活动产生重大影响，立案调查期间， 刘大涛将积极配合中国证监会开展调查工作。 个人简历显示，刘大涛于1972年4月出生，药物化学专业博士，高级工程师。 在进入迈威生物前，刘大涛长期从 ...

Core Viewpoint - The company, Maiwei Biotech, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading involving its chairman and general manager, Liu Datao, but this investigation is stated to not significantly impact the company's daily operations [1] Group 1: Company Overview - Maiwei Biotech is an innovative biopharmaceutical company with a full industry chain layout, focusing on products such as antibodies, ADC drugs, recombinant proteins, and small molecule chemical drugs [3] - The company has not yet achieved profitability and has accumulated losses exceeding 3 billion yuan over the past three years [5] Group 2: Financial Performance - From 2022 to 2024, the company's net profits were reported as -955 million yuan, -1.053 billion yuan, and -1.044 billion yuan respectively, indicating consistent losses [5] - In 2024, the company achieved approximately 200 million yuan in revenue, representing a year-on-year growth of 56.28%, while still reporting a net loss of 1.044 billion yuan [5] Group 3: Funding and Market Position - Maiwei Biotech was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in January 2022, raising a net amount of 3.303 billion yuan [7] - The company is currently advancing its IPO process in Hong Kong, having submitted an application to the Hong Kong Stock Exchange for H-share listing on January 6, 2025 [7] - As of May 9, the company's stock price closed at 19.99 yuan per share, with a total market capitalization of 7.988 billion yuan [7]

Core Viewpoint - Insilico Medicine, an AI pharmaceutical company, has submitted its IPO application for the third time after previous attempts failed, indicating a prolonged journey of nearly two years towards going public [1] Group 1: Business Overview - Insilico Medicine operates in three main segments: drug discovery and pipeline development, software solutions, and other discoveries related to non-pharmaceutical fields [2] - The company utilizes its generative AI platform, Pharma.AI, to discover new drug targets related to diseases and to identify promising drug candidates for further development [2] - Currently, the company's drug candidates have not yet been commercialized, with revenue primarily generated from licensing agreements for three candidate drugs [2] Group 2: Financial Performance - Insilico Medicine's revenue for the years 2022 to 2024 was approximately $30.15 million, $51.18 million, and $85.83 million, respectively [3] - The company's net losses for the same years were approximately $222 million, $212 million, and $17 million, respectively [3] Group 3: Funding and Investment - The AI pharmaceutical sector is rapidly evolving, with Insilico Medicine completing multiple funding rounds since its establishment in 2014, attracting notable venture capital and industry investors [4] - The latest funding round, an E round, raised $110 million, led by Hillhouse Capital and involving several prominent investors [4] - The funds raised will accelerate the development of the company's drug pipeline and AI platform [4] Group 4: Industry Context - In 2024, global financing for AI-driven drug development reached $5.8 billion across 128 deals, highlighting the industry's attractiveness to investors despite the lack of profitable standalone AI pharmaceutical companies [5]

Core Viewpoint - India is proposing to significantly reduce its tariff gap with the US from nearly 13% to below 4% in exchange for exemptions from current and potential tariff increases by the Trump administration, marking a substantial shift in trade policy aimed at lowering trade barriers [1][2] Group 1: Trade Negotiations - The average tariff gap between India and the US will decrease by 9 percentage points, reflecting India's commitment to reducing trade barriers [1] - The total bilateral trade between India and the US is projected to be approximately $129 billion in 2024, with India currently enjoying a trade surplus of $45.7 billion [1] - An Indian official indicated that Japan is next in line for a trade agreement with the US after the UK, highlighting India's strategic approach to trade negotiations [1] Group 2: Market Access and Tariff Reductions - India has offered preferential market access for nearly 90% of goods imported from the US, including a reduction in tariffs [2] - Key export sectors such as gems and jewelry, leather, textiles, and horticultural products are seeking preferential market access to enhance trade conditions compared to other US trading partners [2] - India is also looking to ease export regulations on high-value US goods, including aircraft, luxury cars, and pharmaceuticals, to make the agreement more appealing to Washington [2] Group 3: Technology and Equal Treatment - India is requesting equal treatment in key technology sectors such as AI, telecommunications, biotechnology, pharmaceuticals, and semiconductors, similar to that afforded to US allies like the UK, Australia, and Japan [2]

百图生科技术副总裁张晓明（图片来源：受访者提供） 新药研发是人类发展中极具风险和复杂度、耗时最漫长的技术研究领域之ー。 今年1月，英国《自然》杂志子刊《自然医学》（Nature Medicine）发表的一篇论文显示，平均而言， 新药的研发投入约26亿美元，可能需要耗时12-15年，但不幸的是，即使在临床试验阶段，新药的成功 率也低于10%。 上述论文认为，新药研发复杂的原因在于，传统药物研发依赖于药物开发人员的经验和反复试验，尤其 寻找潜在候选药物需要探索的化学空间之大，而且监管要求非常严格，满足安全性、有效性和质量标准 可能是一项耗时且成本高昂的工作。因此，为了克服这些挑战，科学家们一直在积极探索新技术和新方 法，以改进药物开发流程。 如今，AI 技术的出现，尤其是大模型在内的生成式AI技术，融入药物开发流程——靶点识别、药物发 现、临床研究等，有望重塑传统药物研发模式，从而有效提升药物研发效率。 最新数据显示，目前全球已经有3800家企业、4900家投资机构入局AI生物领域，相比四年前笔者发表 的《AI何以成"药神"》深度文章中提到入局的300家企业、880家投资机构，分别增长了1166.7%、 456. ...

Group 1 - The company Harsanlian (002900) announced that its drug Potassium Chloride and Sodium Chloride Injection has passed the consistency evaluation of generic drug quality and efficacy [1] - This drug is used to treat hypokalemia caused by various reasons, prevent hypokalemia, and address arrhythmias caused by digitalis poisoning [1] - The company is the first in China to pass the consistency evaluation for all three specifications of Potassium Chloride and Sodium Chloride Injection, which will enhance the product's technical level and market competitiveness [1]

智通财经记者 | 唐卓雅 智通财经编辑 | 谢欣 5月8日晚间，英矽智能更新招股书，这已经是其第三次递表港交所。 2023年6月、2024年3月，英矽智能曾两次递表，但均因未能在半年内通过聆讯而失效。另外，英矽智能2023年11月10日 曾获中国证监会境外发行上市备案通知书，拟发行不超过7089.05万股境外上市普通股，截至目前备案通知书也已失 效。 英矽智能是一家由生成式人工智能驱动的药物研发公司，成立于2014年，最早起步于美国，并于2019年在中国香港设立 总部。 在最新一版的招股书中，英矽智能称其借助开发平台Pharma.AI生成超20项临床或IND（新药临床试验申请）阶段资 产，其中3项授权给国际药企，合约价值超20亿美元。 其中，英矽智能的核心产品ISM001-055是TNIK的强效选择性抑制剂，作为特发性肺纤维化（IPF）的潜在治疗方案，目 前已进入临床二期阶段。2023年2月，ISM001-055已获得FDA（美国食药监局）授予的孤儿药资格认定。英矽智能预期 2025年上半年就肾纤维化治疗提交IND申请，并于2025年下半年就吸入型ISM001-055用于IPF治疗提交另一项IND申 请。 目 ...

Core Viewpoint - Insilico Medicine, known as the "first stock" in AI drug development, has submitted its application for a Hong Kong IPO after previous setbacks, reflecting both opportunities and challenges in the AI pharmaceutical industry [1][2]. Company Overview - Insilico Medicine was founded in 2014 and established its presence in Shanghai in 2019, leveraging generative AI technology to develop a complete industry chain from target discovery to clinical validation [1]. - The company has undergone eight rounds of financing since 2018, with a post-money valuation of approximately $1.331 billion after a $100 million Series E round in February 2025 [2]. Financial Performance - Insilico Medicine's revenue has shown consistent growth, with figures of approximately $30.1 million, $51.2 million, and $85.8 million for the fiscal years 2022, 2023, and 2024, respectively, representing a revenue growth rate of 185% from 2022 to 2024 [2]. - The gross profit margins have improved significantly, recorded at 63.4%, 75.4%, and 90.4% for the same years [2]. - The adjusted losses have decreased from 70.8 million to 22.7 million over the same period [2]. Use of IPO Proceeds - The funds raised from the IPO are intended for further clinical development of key pipeline candidates, development of new generative AI models, expansion of automated laboratories, and general corporate purposes [2]. Industry Context - The AI-driven pharmaceutical sector is experiencing significant growth, with AI applications potentially increasing the success rate of new drug development from 12% to approximately 14%, saving the biopharmaceutical industry around $1 billion in R&D costs [4]. - In 2022, there were 144 financing events in the AI drug development sector, totaling $6.202 billion, indicating strong market interest, although 2023 saw a decline in financing events and amounts [4]. Challenges in AI Drug Development - Despite the rapid development of AI in pharmaceuticals, challenges remain in commercialization due to technical, data, regulatory, and market acceptance barriers [3]. - The domestic AI pharmaceutical sector is still in early financing stages, with most companies not yet reaching Series C funding [5]. - The reliance on incomplete and inconsistent external data may affect the accuracy of AI models used by Insilico Medicine [10]. Future Prospects - Insilico Medicine's ISM001-055, a selective TNIK small molecule inhibitor, is progressing rapidly through clinical trials, with plans for further studies in China and the U.S. [6][7]. - The overall market for AI in drug development is projected to reach $530 billion by 2030, contingent on successful integration of AI technologies and regulatory cooperation [11].

文 | 港股研究社 《福布斯》2025全球亿万富豪榜揭晓时，历史正在完成一场静默的交接。 马斯克、扎克伯格等互联网时代的"造富图腾"依然屹立潮头，但榜单背后涌动的暗流已悄然转向。 AI数据标注独角Scale AI联合创始人兼首席执行官Alexandr Wang，成为最年轻的白手起家亿万富翁。这家公司另一位联合创始人郭露西，也超越美国歌手泰 勒·斯威夫特成为全球最年轻的白手起家女性亿万富豪。 19岁华裔男孩与21岁女生一起创业，缔造了一家估值超过250亿美元的科技公司，90后创业者们推动了财富的代际更迭。 类似的故事也在大洋彼岸上演。90后"天才少年"彭志辉创立的具身智能公司智元机器人估值突破150亿元，Manus创始人肖弘让各界将目光进一步聚焦向AI Agent（智能体）。 毫无疑问，一场堪比互联网更深刻的财富风暴已席卷而来。未来十年的投资密码，正藏在这群年轻人"奔赴未见世界"的野望中。 天才"90后"崛起：AI时代的造富新故事 最近一段时间，华裔科技创业者Lucy Guo（郭露西）火出圈了。 凭借手中近5%的Scale AI股份，郭露西击败霉霉成为全球最年轻的白手起家女性亿万富豪。 Scale AI为Ope ...

证券代码：300199 证券简称：翰宇药业 深圳翰宇药业股份有限公司 投资者关系活动记录表 编号：2025-001 | | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | 投资者关系活动类别 | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） 个人投资者：线上参与公司2024年度暨2025第一季度网上业绩说明 | | | 会的投资者 | | | 机构投资者（排名不分先后）：中信建投、国盛证券、民生证券、方 | | 参与单位名称及人员姓名 | 正证券、华福证券、中泰证券、招商证券、国联民生证券、信达证券、 | | | 兴业证券、财通证券、东方证券、国投证券、浙商证券、申万宏源研 | | | 究、华创证券、华安证券、Citi等多家机构 | | 时间 | 2025年05月08日 15:30-17:00 | | 地点 | 东方财富路演（https://roadshow.eastmoney.com/）网络互动 | | 上市公司接待人员姓名 | 董事长、总裁 曾少贵 | | | 董事、执行总裁 PINXIANG YU ...